Asset Details
Do you wish to reserve the book?
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
Do you wish to request the book?
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
2017
Overview
The expression of Programmed cell Death Ligand 1 (PD-L1) is observed in many malignant tumors and is associated with poor prognosis including Gastric Cancer (GC). The relationship between PD-L1 expression and prognosis, however, is controversial in GC. This paper purports to use a meta-analysis to investigate the relationship between PD-L1 expression and prognosis in GC. For this study, the following databases were searched for articles published from June 2003 until February 2017: PubMed, EBSCO, Web of Science and Cochrane Library. The baseline information extracted were: authors, year of publication, country where the study was performed, study design, sample size, follow-up time, baseline characteristics of the study population, pathologic data, overall survival (OS). A total of 15 eligible studies covering 3291 patients were selected for a meta-analysis based on specified inclusion and exclusion criteria. The analysis showed that the expression level of PD-L1 was associated with the overall survival in GC (Hazard Ratio, HR = 1.46, 95%CI = 1.08-1.98, P = 0.01, random-effect). In addition to the above, subgroup analysis showed that GC patients with deeper tumor infiltration, positive lymph-node metastasis, positive venous invasion, Epstein-Barr virus infection positive (EBV+), Microsatellite Instability (MSI) are more likely to expression PD-L1. The results of this meta-analysis suggest that GC patients, specifically EBV+ and MSI, may be prime candidates for PD-1 directed therapy. These findings support anti-PD-L1/PD-1 antibodies as a kind of immunotherapy which is promising for GC.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Bias
/ Biomarkers, Tumor - metabolism
/ Cancer
/ Epstein-Barr Virus Infections - metabolism
/ Epstein-Barr Virus Infections - mortality
/ Epstein-Barr Virus Infections - pathology
/ Humans
/ Ligands
/ Lymph
/ Medicine
/ Medicine and Health Sciences
/ Patients
/ Quality
/ Research and Analysis Methods
/ Stomach Neoplasms - metabolism
/ Stomach Neoplasms - mortality
/ Stomach Neoplasms - pathology
/ Stomach Neoplasms - virology
/ Studies
/ Surgery
/ Survival
/ Tumors
/ Viruses
